Table 1.
Characteristics of included studies
| SN | Studies (Year) | Type of study (centre) | No of patients | Patient condition | Time of administration | Dosage of CPT | Antibody titer | Concomitant therapy | Author's conclusion |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Chen et al 24 | Retrospective Observational, MC | 29 | Severely ill | 19 d (IQR, 14‐20) | 200‐500 mL (4‐5 mL/kg) | >1:160 | Not specified | Significant improvement in clinical outcomes in comparison to the untreated cases |
| 2 | Duan et al 25 | Pilot prospective cohort with a historical control group, SC | 20 | Severely ill | 16.5 d (IQR, 11‐19) | 200 mL | >1:640 | antiviral therapy, steroids and supportive care as appropriate | CPT shows a potential therapeutic effect and low risk in the treatment of severe COVID‐19 patients |
| 3 | Gharbharan et al 26 | Open‐label RCT, MC | 86 | Mild‐ moderately ill | 9 d (IQR, 7‐13) | 300 mL | 1:640 (IQR, 1:320‐1:1280) | Chloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, anakinra as appropriate | No statistically significant differences in mortality (OR, 0.95, CI, 0.20‐4.67; P = .95) or improvement in the day‐15 disease severity (OR, 1.30; CI, 0.52‐3.32; P = .58) was observed when the study was suspended |
| 4 | Joyner et al 27 | Observational CT, MC | 5000 | Critically ill | Not specified | 200‐500 mL | Not specified | Not specified | Seven‐day mortality rate = 14.9% |
| 5 | Li et al 28 | Open label RCT, MC | 103 | Critically ill | 27 d (IQR, 22‐39) | 4‐13 mL/kg 200 mL (IQR, 200‐300) | >1:640 | antivirals, steroids, immunoglobulin, antibiotics and Chinese herbal medicines, as appropriate | In severe or life‐threatening COVID‐19 patients, in addition to standard treatment, CPT did not result in a statistically significant improvement in time to clinical improvement within 28 d. Interpretation is limited by early termination of the trial |
| 6 | Liu et al 29 | Case controlled study, SC | 185 | Moderate‐ critically ill | 4 d (IQR, 1‐7) | 2 units. Each unit of 250 mL | >1:320 | antivirals, anti‐biotics, steroid and immunoglobulins as appropriate | Plasma recipients also demonstrated improved survival, compared to control patients |
| 7 | Zeng et al 30 | Retrospective observational study, MC | 21 | Critically ill | 21.5 d (IQR, 17.8‐23) | 300 mL (IQR, 200‐600) | Not specified | antivirals, steroid and immunoglobulins as appropriate | CPT can discontinue the viral shedding and contribute longer survival duration in COVID‐19 patients with respiratory failure, although it cannot reduce the mortality in critically end‐stage patients |
Abbreviations: CPT, convalescent plasma transfusion; IQR, interquartile range; MC, multi‐center; OR, odds ratio; RCT, randomized controlled trial; SC, single center.